Ametris - formerly ActiGraph

05/27/2026

New Article Alert: Digital Health Technology for the Early Detection of CRS in Decentralized Oncology Trials

We’re excited to share this new article in International Clinical Trials by Michael Pettinati and Samantha McClenahan about how continuous remote monitoring can derisk CRS and enable safer outpatient delivery and broader patient access to life-changing immunotherapy.

Read the full piece, and join us for a webinar tomorrow where the authors will provide additional insights into CRS detection and management and introduce DECODE CRS, a new precompetitive coalition that is tackling this industry-wide challenge head-on: https://hubs.la/Q04hYRBN0

05/20/2026

Behind the tremendous amount of work and dedication required to bring new therapies to market are real people navigating real-life challenges and experiences. Today, we thank and honor patients for International Clinical Trials Day. Their contributions make medical innovation possible.

Explore our Patient Voice Library to hear first hand patient accounts of the most impactful symptoms of their conditions and learn how DHTs can help us better understand how they feel and function in their everyday lives. Link below in the comments ⤵️

05/19/2026

Immunotherapy treatments such as CAR-T and T-cell engagers (TcEs) are transforming patient care across oncology and immunology—but access remains limited by variability in monitoring, inconsistent data collection, and a lack of standardization across care settings.

Join us on next week on Wednesday, May 27th for our next Digital Health Monthly webinar: Scaling Access to Immunotherapy Treatments Through Pre-Competitive Collaboration: Introducing the DECODE CRS Coalition

During the webinar, a multidisciplinary panel of experts from Boehringer Ingelheim, the Digital Medicine Society (DiMe), National Cancer Institute, Genentech, and Ametris will explore how fit-for-purpose DHTs and precise, standardized data collection can provide a more continuous, objective view of the patient experience following immunotherapy infusion. These advances support earlier detection of change, increase confidence in care decisions, and enable more scalable treatment models through outpatient and community-based care.

We will also introduce the DECODE CRS Coalition and share why this pre-competitive, collaborative approach is critical to advancing system-wide solutions that enable safer care, broader access to life-changing immunotherapies, and improved patient outcomes in real-world settings.

Register now: https://hubs.la/Q04h7XMj0

Can’t make the live webinar? Register now and you’ll receive the on-demand recording in your inbox!

05/18/2026

The industry-wide shift toward precise digital health technologies (DHTs) allows clinical research teams to capture a more complete view of patient function and behavior over time. However, the promise of DHT cannot be realized without consistent device adherence. When patients do not wear their devices, missing data can undermine endpoint integrity and create costly risks for clinical studies.

With flexible monitoring approaches tailored to different study goals and operational needs, Ametris’ ActiTrack adherence solutions help study teams proactively identify risks, intervene when needed, and maximize data completeness.

To learn more about the most advanced DHT adherence monitoring solution in the industry, visit: https://hubs.la/Q04h22FR0 https://hubs.la/Q04h22FR0

05/18/2026

Join the Ametris team at ACSM 2026 in Salt Lake City, Utah on May 26-29!

If you'll be attending , we'd love to discuss how our wearable technology solutions can help you achieve your research objectives. Reach out to Hayden Davis and Madisen Pooton directly in advance, or schedule a meeting using the link below. We hope to see you in Salt Lake City!

Schedule a meeting: https://hubs.la/Q04h22Bl0

05/14/2026

An Exciting New Chapter for Digital Health in Clinical Research!

Today, we’re proud to share that Ametris is now a Signant Health company.

This strategic acquisition brings together industry-leading eCOA solutions with validated, wearable-derived digital outcome measures for the first time. By integrating patient-reported outcomes with continuous sensor data through a single, coordinated platform, Ametris and Signant are helping shape a new era of clinical research defined by deeper patient insights, stronger efficacy evidence, and more streamlined clinical trial ex*****on.

Together, we believe this powerful alliance will help transform how clinical trials are designed, conducted, and measured by simplifying fragmented technology ecosystems while enabling richer, more connected patient data.

Read the full announcement to learn more: https://hubs.la/Q04gCz0H0

05/12/2026

In oncology research, capturing meaningful patient data without adding burden remains a major challenge that contributes to slower adoption of DHTs compared to other therapeutic areas.

In the Phase 3 LIBERTAS trial for metastatic castration-sensitive prostate cancer (mCSPC), Johnson & Johnson Innovative Medicine achieved nearly 90% wearable adherence over 12+ months of actigraphy monitoring using a real-time, intervention workflow.

Check out our newest case study to explore how implementation of a data-driven intervention strategy can increase sustained wearable adherence, improve data completeness, and reduce variability in long-duration oncology studies involving older, clinically complex populations.

Access the case study: https://hubs.la/Q04gj5RD0

05/08/2026

Traditional endpoints for Huntington’s Disease (HD) may not capture the subtle, real-world manifestations of motor and non-motor symptoms experienced in daily life. As the field moves toward earlier interventions, there is a need for more sensitive and longitudinal measurement tools.

In case you missed last week's webinar on Huntington’s Disease clinical research and digital health technology, watch the on-demand recording with expert-led technical insights:
https://hubs.la/Q04f-R9G0

Explore data-driven health insights with 'Digital Health Monthly' webinar series. Join expert panels to uncover digital health advancements. Watch now!

05/07/2026

Immunotherapy treatments such as CAR-T and T-cell engagers (TcEs) are transforming patient care across oncology and immunology—but access remains limited by variability in monitoring, inconsistent data collection, and a lack of standardization across care settings.

Join us on Wednesday, May 27th for our next Digital Health Monthly webinar:

Scaling Access to Immunotherapy Treatments Through Pre-Competitive Collaboration: Introducing the DECODE CRS Coalition

During the webinar, a multidisciplinary panel of experts from Boehringer Ingelheim, the Digital Medicine Society (DiMe), and Ametris will explore how fit-for-purpose DHTs and precise, standardized data collection can provide a more continuous, objective view of the patient experience following immunotherapy infusion. These advances support earlier detection of change, increase confidence in care decisions, and enable more scalable outpatient and community-based care treatment models.

We will also introduce the DECODE CRS Coalition and share why this pre-competitive, collaborative approach is critical to advancing system-wide solutions that enable safer care, broader access to life-changing immunotherapies, and improved patient outcomes in real-world settings.

Register now: https://hubs.la/Q04fQXGp0

Can’t make the live webinar? Register now and you’ll receive the on-demand recording in your inbox!

05/04/2026

Huntington’s disease (HD) presents complex clinical trial challenges due to its subtle early-stage progression and the limitations of traditional, subjective rating scales. To overcome these hurdles, researchers are moving toward digital health technologies that offer more sensitive, objective, and continuous measurement of real-world patient experiences.

Ametris' Rakesh Pilkar, Lead of DHT Solutions in Neuroscience, synthesizes key takeaways from our recent ADDS 2026 pre-conference workshop on reshaping HD outcome measurements, featuring expert perspectives from Michelle Campbell from the FDA, Lori Quinn from Columbia University, Jamie Adams from University of Rochester Medical, Jonas Dorn from Roche, and Swati Sathe and Matthew Roche from the CHDI Foundation.

Read the article using the link below in the comments 👇

04/23/2026

We’re excited to announce that Ametris team members Michael Pettinati and Sean Smith will be attending in Chicago next month.

An abstract co‑authored by senior data scientist Michael Pettinati, PhD, and Jonas Paludo, MD of Mayo Clinic has been accepted for poster presentation. Dr. Paludo will present the poster, which highlights new data on how continuous wearable monitoring enables earlier CRS identification in outpatient CAR T‑cell therapy, emphasizing the critical role of real‑time data in improving patient safety and care delivery for complex biopharma treatments.

Schedule some time with one of our team members to talk more in advance: https://hubs.la/Q04dhbFF0